• Home
  • About Us
    • Who we are
    • Our Early History
    • Technology
    • Target Markets
      • Venous and pressure ulcers
      • Other Applications
    • Business Model
    • Licensing
    • Clinical Trial
    • Publications & Presentations
    • Company Milestones
    • Focus
  • The Company
    • Board & Management
      • Paul Wright
      • Mark Richardson
      • George Baumanis
      • Stuart Usher
  • Advisory Team
    • Intellectual Property
      • Vaughan Barlow
      • Tom Boyce
      • Audrey Yap
      • Yvette Flanigan
    • Principal Advisor
      • Mark Woolley
    • Medical and Scientific Advisory Committee
      • James Fries
      • Michael Woodward
    • Scientific
      • Richard Lipscombe
    • Clinical
      • Geoffrey Mitchell
    • Health Economics
      • Nicholas Graves
  • Media
  • Links
  • Members Log in
  • Contact Us

News Headlines

> 18/01/10
Phoenix Eagle commences clinical trial.


> 01/12/09
OPAL A-1001 clinical trial has been approved by the Human Research Ethics Committee of the Austin Hospital.

Our Target Markets – Venous and Pressure Ulcers

Initially, Phoenix Eagle’s target market is for the treatment of venous ulcers and pressure ulcers (bed sores).

Rates of failure with standard care of venous and pressure ulcers remain unacceptably high, and there are no reliable treatment alternatives that address the needs of “hard-to-heal” venous and pressure ulcer patients.

The Phoenix Eagle Company Pty Ltd website is proudly maintained by NetBiz Enterprises.